Until prospective randomized clinical data accrue and mature, this controversial issue will continue to suffer from overinterpretation of inadequate supporting data.
Vivek Verma, MD
Advertisement
Articles by Vivek Verma, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Relacorilant Combo in Platinum-Resistant Ovarian Cancers
2
Bevacizumab Biosimilar Shows Clinical Equivalence in Advanced NSCLC
3
Nadofaragene Firadenovec Label Update Approved in BCG-Unresponsive NMIBC
4
IMNN-001 Plus Neoadjuvant Chemo Improves OS in Advanced Ovarian Cancer
5